Estimation of serum TSH receptor autoantibody concentration and affinity

We have used the human monoclonal TSH receptor (TSHR) autoantibody (M22) as a labeled ligand in competition with individual patient TSHR autoantibodies (TRAb) to estimate their serum concentrations and affinities. TSHR coated tubes, (125)I-labeled M22 IgG and Fab, and patient sera IgG and Fab were u...

Full description

Saved in:
Bibliographic Details
Published in:Thyroid (New York, N.Y.) Vol. 16; no. 11; p. 1077
Main Authors: Nakatake, Nobuhiro, Sanders, Jane, Richards, Tonya, Burne, Peter, Barrett, Carol, Pra, Chiara Dal, Presotto, Fabio, Betterle, Corrado, Furmaniak, Jadwiga, Smith, Bernard Rees
Format: Journal Article
Language:English
Published: United States 01.11.2006
Subjects:
Antibodies, Monoclonal - pharmacology
Antibody Affinity
Autoantibodies - blood
Binding, Competitive - immunology
Chromatography, Affinity
Graves Disease - immunology
Humans
Immunoglobulin Fab Fragments - blood
Immunoglobulin Fab Fragments - pharmacology
Immunoglobulin G - blood
Immunoglobulin G - pharmacology
Immunoglobulins, Thyroid-Stimulating
Iodine Radioisotopes
Receptors, Thyrotropin - immunology
Receptors, Thyrotropin - metabolism
Thyrotoxicosis - immunology
ISSN:1050-7256
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We have used the human monoclonal TSH receptor (TSHR) autoantibody (M22) as a labeled ligand in competition with individual patient TSHR autoantibodies (TRAb) to estimate their serum concentrations and affinities. TSHR coated tubes, (125)I-labeled M22 IgG and Fab, and patient sera IgG and Fab were used in these studies. In 15 patients with Graves' disease, TRAb concentrations ranged from 50 to 500 ng/mL of serum (5- 60 parts per million of total serum IgG) and TRAb IgG affinities from 3.0 +/- 1.0-6.7 +/- 1.54-10(10) L/mol (mean +/- SD; n=3). Fab fragment affinities were similar to those of intact IgG. Serum TRAb with blocking (TSH antagonist; 4 patients) activity had similar affinities (3.0 +/- 0.25-7.2 +/- 2.2-10(10) L/mol) to TRAb IgG from patients with Graves' disease, but blocking TRAb concentrations were higher (1.7 - 27 mg/mL of serum). The concentrations of TRAb that we observed in the sera of the 15 Graves' patient (0.33 - 3.3 nmol/L) can be compared with that of circulating TSH. In particular, a serum TSH concentration of 100mU/L (0.7 nmol/L) is in the same range as the concentrations of TRAb we observed. Such a TSH concentration (similar to that observed after injection of 0.9 mg of recombinant human TSH) would be expected to cause a similar degree of thyrotoxicosis as seen in Graves' disease. Consequently, the thyroid-stimulating potencies (i.e., activity per mol) of patient serum TRAb and human TSH appear to be of a similar magnitude in vivo as well as in vitro. Overall, our results indicate that serum TRAb affinities are high and show only limited variations between different sera whereas concentrations of the autoantibodies vary widely.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1050-7256
DOI:10.1089/thy.2006.16.1077